Clinical Trial Update: Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lapatinib plus capecitabine as second-line treatment for pancreatic cancer was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Tykerb (lapatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Georgetown University | Conditions: Pancreas Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-06